These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 39117621)
41. A single-valent long-acting human CD47 antagonist enhances antibody directed phagocytic activities. Wu F; Qiu Y; Xu Y Cancer Immunol Immunother; 2020 Dec; 69(12):2561-2569. PubMed ID: 32583154 [TBL] [Abstract][Full Text] [Related]
42. CD47/SIRPα axis: bridging innate and adaptive immunity. van Duijn A; Van der Burg SH; Scheeren FA J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35831032 [TBL] [Abstract][Full Text] [Related]
43. DSP107 combines inhibition of CD47/SIRPα axis with activation of 4-1BB to trigger anticancer immunity. Cendrowicz E; Jacob L; Greenwald S; Tamir A; Pecker I; Tabakman R; Ghantous L; Tamir L; Kahn R; Avichzer J; Aronin A; Amsili S; Zorde-Khvalevsky E; Gozlan Y; Vlaming M; Huls G; van Meerten T; Dranitzki ME; Foley-Comer A; Pereg Y; Peled A; Chajut A; Bremer E J Exp Clin Cancer Res; 2022 Mar; 41(1):97. PubMed ID: 35287686 [TBL] [Abstract][Full Text] [Related]
44. A homogeneous SIRPα-CD47 cell-based, ligand-binding assay: Utility for small molecule drug development in immuno-oncology. Burgess TL; Amason JD; Rubin JS; Duveau DY; Lamy L; Roberts DD; Farrell CL; Inglese J; Thomas CJ; Miller TW PLoS One; 2020; 15(4):e0226661. PubMed ID: 32240171 [TBL] [Abstract][Full Text] [Related]
45. Modulation of CD47-SIRPα innate immune checkpoint axis with Fc-function detuned anti-CD47 therapeutic antibody. Narla RK; Modi H; Bauer D; Abbasian M; Leisten J; Piccotti JR; Kopytek S; Eckelman BP; Deveraux Q; Timmer J; Zhu D; Wong L; Escoubet L; Raymon HK; Hariharan K Cancer Immunol Immunother; 2022 Feb; 71(2):473-489. PubMed ID: 34247273 [TBL] [Abstract][Full Text] [Related]
46. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Willingham SB; Volkmer JP; Gentles AJ; Sahoo D; Dalerba P; Mitra SS; Wang J; Contreras-Trujillo H; Martin R; Cohen JD; Lovelace P; Scheeren FA; Chao MP; Weiskopf K; Tang C; Volkmer AK; Naik TJ; Storm TA; Mosley AR; Edris B; Schmid SM; Sun CK; Chua MS; Murillo O; Rajendran P; Cha AC; Chin RK; Kim D; Adorno M; Raveh T; Tseng D; Jaiswal S; Enger PØ; Steinberg GK; Li G; So SK; Majeti R; Harsh GR; van de Rijn M; Teng NN; Sunwoo JB; Alizadeh AA; Clarke MF; Weissman IL Proc Natl Acad Sci U S A; 2012 Apr; 109(17):6662-7. PubMed ID: 22451913 [TBL] [Abstract][Full Text] [Related]
47. Blocking CD47 efficiently potentiated therapeutic effects of anti-angiogenic therapy in non-small cell lung cancer. Zhang X; Wang Y; Fan J; Chen W; Luan J; Mei X; Wang S; Li Y; Ye L; Li S; Tian W; Yin K; Ju D J Immunother Cancer; 2019 Dec; 7(1):346. PubMed ID: 31829270 [TBL] [Abstract][Full Text] [Related]
49. Biomimetic Nano-Degrader Based CD47-SIRPα Immune Checkpoint Inhibition Promotes Macrophage Efferocytosis for Cardiac Repair. Gao J; Pang Z; Wang Q; Tan Y; Li Q; Tan H; Chen J; Yakufu W; Wang Z; Yang H; Zhang J; Sun D; Weng X; Wang Q; Qian J; Song Y; Huang Z; Ge J Adv Sci (Weinh); 2024 Jun; 11(24):e2306388. PubMed ID: 38477522 [TBL] [Abstract][Full Text] [Related]
50. A Glutamine-Rich Carrier Efficiently Delivers Anti-CD47 siRNA Driven by a "Glutamine Trap" To Inhibit Lung Cancer Cell Growth. Wu J; Li Z; Yang Z; Guo L; Zhang Y; Deng H; Wang C; Feng M Mol Pharm; 2018 Aug; 15(8):3032-3045. PubMed ID: 29939755 [TBL] [Abstract][Full Text] [Related]
51. Functional CD47/signal regulatory protein alpha (SIRP(alpha)) interaction is required for optimal human T- and natural killer- (NK) cell homeostasis in vivo. Legrand N; Huntington ND; Nagasawa M; Bakker AQ; Schotte R; Strick-Marchand H; de Geus SJ; Pouw SM; Böhne M; Voordouw A; Weijer K; Di Santo JP; Spits H Proc Natl Acad Sci U S A; 2011 Aug; 108(32):13224-9. PubMed ID: 21788504 [TBL] [Abstract][Full Text] [Related]
52. Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors. Miller TW; Amason JD; Garcin ED; Lamy L; Dranchak PK; Macarthur R; Braisted J; Rubin JS; Burgess TL; Farrell CL; Roberts DD; Inglese J PLoS One; 2019; 14(7):e0218897. PubMed ID: 31276567 [TBL] [Abstract][Full Text] [Related]
53. Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα-CD47 innate immune checkpoint. Voets E; Paradé M; Lutje Hulsik D; Spijkers S; Janssen W; Rens J; Reinieren-Beeren I; van den Tillaart G; van Duijnhoven S; Driessen L; Habraken M; van Zandvoort P; Kreijtz J; Vink P; van Elsas A; van Eenennaam H J Immunother Cancer; 2019 Dec; 7(1):340. PubMed ID: 31801627 [TBL] [Abstract][Full Text] [Related]
54. Progress of CD47 immune checkpoint blockade agents in anticancer therapy: a hematotoxic perspective. Chen YC; Shi W; Shi JJ; Lu JJ J Cancer Res Clin Oncol; 2022 Jan; 148(1):1-14. PubMed ID: 34609596 [TBL] [Abstract][Full Text] [Related]
55. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy. Schürch CM; Roelli MA; Forster S; Wasmer MH; Brühl F; Maire RS; Di Pancrazio S; Ruepp MD; Giger R; Perren A; Schmitt AM; Krebs P; Charles RP; Dettmer MS Thyroid; 2019 Jul; 29(7):979-992. PubMed ID: 30938231 [No Abstract] [Full Text] [Related]
56. Functional elements on SIRPalpha IgV domain mediate cell surface binding to CD47. Liu Y; Tong Q; Zhou Y; Lee HW; Yang JJ; Bühring HJ; Chen YT; Ha B; Chen CX; Yang Y; Zen K J Mol Biol; 2007 Jan; 365(3):680-93. PubMed ID: 17070842 [TBL] [Abstract][Full Text] [Related]
57. SIRPα-antibody fusion proteins stimulate phagocytosis and promote elimination of acute myeloid leukemia cells. Ponce LP; Fenn NC; Moritz N; Krupka C; Kozik JH; Lauber K; Subklewe M; Hopfner KP Oncotarget; 2017 Feb; 8(7):11284-11301. PubMed ID: 28061465 [TBL] [Abstract][Full Text] [Related]
58. CD47-SIRPα Controls ADCC Killing of Primary T Cells by PMN Through a Combination of Trogocytosis and NADPH Oxidase Activation. Gondois-Rey F; Miller T; Laletin V; Morelli X; Collette Y; Nunès J; Olive D Front Immunol; 2022; 13():899068. PubMed ID: 35795660 [TBL] [Abstract][Full Text] [Related]
60. Lipid-mediated delivery of CD47 siRNA aids JQ1 in ensuring simultaneous downregulation of PD-L1 and CD47 and improves antitumor immunotherapy efficacy. Li Y; Meng X; Chen G; Hou Y; Wu X; Wang J; Cong X; Mao K; Wu C; Chen H; Sun X; Zhou J; Wang Y; Yang YG; Sun T Biomater Sci; 2022 Nov; 10(23):6755-6767. PubMed ID: 36301154 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]